Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
about
Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeabilityIL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway.Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD.Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammationInterleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage.Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo.Promising effect of Magliasa, a traditional Iranian formula, on experimental colitis on the basis of biochemical and cellular findings.Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammationThe role of IL-33 in gut mucosal inflammation.Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activationUrinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- miceExaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.Involvement of JAK-STAT signaling/function after cyclophosphamide-induced bladder inflammation in female rats.Cellular and molecular mechanism of interleukin-1β modulation of Caco-2 intestinal epithelial tight junction barrier.IL1beta- and LPS-induced serotonin secretion is increased in EC cells derived from Crohn's disease.Hyperosmotic stress induces nuclear factor-kappaB activation and interleukin-8 production in human intestinal epithelial cells.The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes.Effect of proinflammatory interleukins on jejunal nutrient transport.Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis.Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro.
P2860
Q24317362-9997A652-2DF3-4A9C-A1F9-6B5295B625C0Q34254423-3B50C662-18C5-4334-9592-5D64ADF8B94BQ34575468-E47E1E5C-D059-45CD-AA87-BEBCD4BAAC3CQ35191071-15F937BF-5B58-4A3A-8286-28F58A70C1F8Q35594688-01CEB440-86A8-4CFB-8F81-AAB4981225AAQ36296995-990FF3C3-0663-4CD3-84AB-DCA900C73447Q36731168-27A6B547-B9C1-418C-B93A-4FFF773DBB73Q36855014-4DDB87DC-B606-4E58-BDEE-A35E72B27292Q36914110-B742E9E1-E14C-4ED7-987C-9FE5ADCAA131Q36914746-0C8E06A2-A90C-4B84-B01E-E85DE4823B99Q37219681-68DEA5DE-5345-477C-910D-DAA5BD0C604EQ37225300-DCD1A330-B61F-4E63-BB81-637006A5EED8Q37417236-8F0BA194-CF6A-45EF-B04B-380750AB2406Q37580772-0082681B-33BB-4FEC-8F1E-E1FA2DACC4F3Q40147698-3985873E-CAAC-4947-9AA8-97F37299672DQ41820555-1DEC9E81-9183-43A0-A7A0-2B9DA32326E9Q41900249-38F0DD0A-1A10-4BDD-8CD1-5957D14E4BBAQ42259565-FF101556-57B0-4E2B-B304-E4C6260825BCQ49472652-516B92B1-9604-4194-B2A5-11C7C0CFA616Q55335592-C81A46B3-0C41-4105-8151-440AC71F692C
P2860
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@ast
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@en
type
label
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@ast
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@en
prefLabel
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@ast
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@en
P1476
Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
@en
P2093
Cominelli F
Pizarro TT
P304
49-53; discussion 54
P407
P478
10 Suppl 2
P577
1996-01-01T00:00:00Z